Widening Pharma Pessimism On China Amid Falling Profitability
This article was originally published in PharmAsia News
Executive Summary
Despite the health care sector generally faring well in the general economic slowdown in China, pharma companies say they are becoming less profitable in this market, and are still concerned about IPR and regulatory reform issues, notes a new European Chamber of Commerce business confidence survey.